Runninghead: FGFR3 in invasive bladder cancer and matched metastases
FGFR3 expression in matched primary and metastasized bladder cancer showed good but not absolute concordance. We conclude that in the majority of patients FGFR3 status of the primary tumor can guide selection of FGFR-targeted therapy.
INTRODUCTION
Fibroblast growth factor receptor 3 (FGFR3) is commonly activated by mutation, overexpression or chromosomal translocation in UC of the bladder. [1] [2] [3] Up to 80% of superficial papillary tumors and 10-20% of muscle-invasive tumors contain activating point mutations. In advanced UC, the most common finding is upregulated expression of wildtype FGFR3 in 40-50% of cases. 2 FGFR3 is considered a good therapeutic target in UC. In UC cell lines, inhibition by knockdown, small molecules or antibodies has a profound effect including inhibition of xenograft growth. [4] [5] [6] [7] [8] [9] [10] [11] Several clinical trials of FGFR-targeted agents are now planned or in progress in UC. The use of such inhibitors can be envisaged as part of neoadjuvant treatment or in the metastatic setting. Metastatic disease is the most common cause of death in bladder cancer but currently used chemotherapy regimes have limited efficacy and overall survival is low (10 year-survival for patients with lymph node positive disease ~ 30%). 12 Thus, there is an urgent need for improved approaches to therapy for these patients. FGFR inhibitors may be relevant agents to apply in combination with platinum-based chemotherapy.
Successful treatment of advanced disease must target metastatic lesions. It is not yet clear how closely the molecular profile of metastatic UC mirrors that in the primary tumor. As biopsies of metastases are not routinely available at the time of selection of therapy, it is important to assess whether the primary tumor can act as a surrogate. Few studies have examined UC metastases and to date none have examined FGF receptors.
Therefore, we evaluated the frequency and prognostic impact of FGFR3 protein overexpression in a series of primary UC with matched lymph node metastases treated by radical cystectomy and extended pelvic lymphadenectomy.
MATERIALS AND METHODS

Patients and follow-up
The cohort comprised 150 bladder cancer patients without preoperative evidence of metastases (i.e. by physical examination, chest x-ray, intravenous urography, bone scan, and pelvic computed tomography, when available) but with lymph node metastases on pathologic examination ( was given. Postoperatively, the patients were followed prospectively according to a standard protocol with examinations at the Department of Urology or by urologists in private practice at 3 months and 6 months, then at 6-month intervals until 5 years, and then at yearly intervals thereafter.
Treatment and pathology
All patients were treated by cystectomy and bilateral extended pelvic lymphadenectomy according to standard protocols described previously. 13, 14 The surgical specimens were processed as described previously. 14 Tumors were staged according to the 7th Union
Internationale Contre le Cancer classification.
15
Construction of the tissue microarray
The tissue microarray, which has been used in several previous studies [16] [17] [18] 
Statistical analyses
FGFR3 expression was tested for association with categorical clinical data using Fisher's exact test, and OS and RF) using Kaplan-Meier analysis. Significance of predictors in survival analysis was assessed using the log-rank test for univariate analysis. For the analysis of metastatic tumor phenotype the ratios have been calculated for total and lower metastases' diameter, and total number of metastases. All statistical calculations were carried out with SPSS for Windows version 20. 
RESULTS
FGFR3 protein expression in primary tumors and metastases
Relationship of FGFR3 status with metastatic phenotype
The 
FGFR3 status and adjuvant chemotherapy
A recent study reported that high levels of FGFR3 expression were related to adverse outcome in invasive UC treated with adjuvant chemotherapy 19 . In this series of cases, 63 patients had received adjuvant chemotherapy. In 37 cases, this was cisplatin-based. We examined the relationships of FGFR3 expression in primary and metastastic tissue and chemotherapy (no chemotherapy, any chemotherapy and cisplatin-based chemotherapy)
with overall and recurrence-free survival. No significant relationships were found (Supplementary Figure 3) .
DISCUSSION
Selection of patients for targeted therapies requires knowledge of the presence of the relevant protein target. In non-invasive bladder tumors the presence of FGFR3 mutation shows strong correlation with high protein expression levels 2 , but this relationship is not so clear for advanced bladder cancer. 19 Thus measurement of protein levels rather than mutation status appears most relevant in this group of patients. Our hybridization showed high concordance whilst ERBB2 protein expression showed lower concordance in the tissue samples used here 18 . Unlike expression changes, a genomic alteration is unlikely to be lost from cells following engraftment at a metastatic site, and intra-tumor heterogeneity appears a more likely explanation in this case. More detailed examination of both FGFR3 and ERBB2 in the gross specimens of these tissues will be of great interest.
Our study has some limitations. Despite including a relatively large number of matched samples the study might be underpowered to show statistically significant differences. For example, number of positive nodes and diameter of the metastatic deposits both appeared to show a relationship to FGFR3 status but neither were statistically significant. These features merit investigation in a larger sample series. In this study, we were unable to assess FGFR3 mutation status. Whilst protein levels may be the most relevant measure in invasive bladder tumors, it will be important to confirm this by assessment of both genomic alterations and expression changes in any future studies. The use of a more robust measure of protein expression level, for example by image analysis, may also be included.
The arguments for using IHC to assess therapeutic targets are strong. Targeted therapy works at the protein level and protein expression is not always directly related to genomic features such as mutation or gene amplification. However, one of the limitations of IHC is its variability in reporting. This often reflects differences in antibodies, detection kits, protocols and methods of interpretation. Here we simplified our scoring criteria by grouping samples into only two groups (low and high). Assessment of a therapeutic target has different requirements than assessment of a prognostic indicator.
Thus, scoring based on the worst feature or presence of minor cell population in a tumor may be inappropriate for application in clinical practise and new systems may be required. Our study provides encouragement to now assess gross samples from a similar cohort of patients.
CONCLUSIONS
The expression status of FGFR3 protein in lymph node metastases removed at cystectomy shows good concordance with the expression status of the related primary tumor. We conclude that in the majority of patients, FGFR3 status in primary tumor tissues provides a good surrogate for status of metastatic disease and that therapeutic decisions can be based on this. 
